Oncoral Pharma ApS
Oncoral Pharma ApS was formed in 2013 as a spin-out of Solural Pharma. It is now a virtual company with the main purpose to develop a new oral tablet based on the intravenous chemotherapy agent Irinotecan for treatment of colorectal cancer.
The company is jointly owned by the founders of Solural Pharma and of CAPNOVA, and the project is supported by the Danish Innovation Fund.
The company has developed a unique proprietary formulation of irinotecan. This new drug product has in dogs demonstrated to be consistently absorbed and having less side effects than normal intravenous dosing.
The drug is currently undergoing Human Clinical Studies at Herlev Hospital.